Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Petragen Inc. is a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently. This 1 pending office action is assigned to 1 distinct examiner. The prosecution activity is located within 1 distinct art unit.
The busiest examiner is SZNAIDMAN, MARCOS L. This examiner is responsible for 1 busiest examiner pending office action. Because there is 1 pending office action and 1 distinct examiner, SZNAIDMAN, MARCOS L handles the current workload. This examiner is the only individual from the USPTO listed in the current data.
Practitioners should note that the prosecution strategy depends on the 1 distinct examiner and the 1 distinct art unit. There are no other distinct examiners in this portfolio to provide a comparison of allowance rates. The 1 distinct art unit defines the technical standards for the 1 pending office action in the Biotechnology & Pharmaceuticals field. The singular focus on SZNAIDMAN, MARCOS L means all current feedback originates from one source.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18298059 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | SZNAIDMAN, MARCOS L | 34d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18298059 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | SZNAIDMAN, MARCOS L | 1628 | §112 | Final Rejection | 34d | Pending | Apr 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPetragen Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marcos L Sznaidman has the most, with 1 of Petragen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
